Nuvalent Inc. Class A Common Stock (NUVL)
FairStock Score: 18/100 — RISKY
Key Financials
| Current Price | $123.96 |
| Market Cap | $8.5B |
| P/E Ratio | -20.46 |
| ROE | -41.19% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I approach Nuvalent as a Graham-style analyst would: the company is a clinical-stage biotech with no commercial revenue and an $8.5B market cap at the $123.96 close on 2026-07-21. It is developing zidesamtinib for ROS1-positive non-small cell lung cancer, a serious indication. Any economic moat must come from pipeline success rather than today's income statement. On the supplied figures, the business is not yet self-sustaining: the supplied EPS figure is -$6.06, P/E is -20.46, ROE is -41.19%, and ROCE is -22.51% as FairStock calculations. Trailing free cash flow is -$312.8M, a -3.7% FCF yield on the $8.5B market cap, and the Piotroski F-Score is 1/9. Those are not the marks of a mature compounder. The Altman Z-Score of 32.32 is strong, but for a pre-revenue biotech it mostly reflects equity funding rather than durable operating earnings. Valuation is demanding: P/B is 8.33, the shares sit near the top of a 52-week range of $87.30-$123.99, and the FairStock Score is 18/100. The Lynch category is none because there are only 0 years of filed results and three are needed. Growth depends entirely on pipeline milestones. I would want evidence of trial success, a path to revenue, and a margin of safety before calling this a value opportunity; at today's price, the market is already paying for considerable future success.
In plain English: Nuvalent is a clinical-stage biotech company working on cancer therapies, including a drug for a type of lung cancer. It is not yet selling products, and its financial numbers show losses and more money going out than coming in. Based on the numbers given, the price looks expensive compared with the lack of sales and profits.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-07-21 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer